Literature DB >> 15574437

Reproductive and therapeutic cloning, germline therapy, and purchase of gametes and embryos: comments on Canadian legislation governing reproduction technologies.

L Bernier1, D Grégoire.   

Abstract

In Canada, the Assisted Human Reproduction Act received royal assent on 29 March 2004. The approach proposed by the federal government responds to Canadians' strong desire for an enforceable legislative framework in the field of reproduction technologies through criminal law. As a result of the widening gap between the rapid pace of technological change and governing legislation, a distinct need was perceived to create a regulatory framework to guide decisions regarding reproductive technologies. In this article the three main topics covered in the new legislation are commented on: cloning, germline therapy, and purchase of gametes and embryos. Some important issues also covered in the new legislation, such as privacy and access to information, data protection, identity of donors, and inspection, will not be addressed.

Entities:  

Keywords:  Biomedical and Behavioral Research; Genetics and Reproduction; Legal Approach

Mesh:

Year:  2004        PMID: 15574437      PMCID: PMC1733972          DOI: 10.1136/jme.2002.002170

Source DB:  PubMed          Journal:  J Med Ethics        ISSN: 0306-6800            Impact factor:   2.903


  2 in total

1.  Germ-line gene therapy: keep the window open a crack.

Authors:  Robert Mullan Cook-Deegan
Journal:  Politics Life Sci       Date:  1994-08

2.  Consent or property? Dealing with the body and its parts in the shadow of Bristol and Alder Hey.

Authors:  K Mason; G Laurie
Journal:  Mod Law Rev       Date:  2001-09
  2 in total
  1 in total

Review 1.  The need for regulation in the practice of human assisted reproduction in Mexico. An overview of the regulations in the rest of the world.

Authors:  Alma López; Miguel Betancourt; Eduardo Casas; Socorro Retana-Márquez; Lizbeth Juárez-Rojas; Fahiel Casillas
Journal:  Reprod Health       Date:  2021-11-27       Impact factor: 3.223

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.